Nathan Wong/LinkedIn
Feb 1, 2026, 11:24
Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control
Nathan Wong, Professor and Director, Heart Disease Prevention Program, Division of Cardiology, UC Irvine, shared on LinkedIn:
”Our latest paper in JACC Journals projects approximately 20 million US adults with inadequately controlled LDL-C on statins could benefit from inclisiran treatment, preventing more than 1.6 million ASCVD events over 10 years.”
Read the full article here.
Article: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Authors: Nathan Wong, Hridhay Karthikeyan, Wenjun Fan, Batul Electricwala
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 1, 2026, 11:25Abdul Mannan: Breaking Down the New BSH Hepatitis Guideline for Haemophilia Nurses
-
Feb 1, 2026, 11:10Antonio Ciacciarelli Shares A Comparison of Pragmatic Post-Thrombectomy Prognostic Scores
-
Feb 1, 2026, 10:41Colm Dougan on The Blood Infection That Changed Medicine
-
Feb 1, 2026, 10:25Indunil Karunarathna Breaks Down The Cerebral Venous Sinus Thrombosis
-
Feb 1, 2026, 10:14Jesse Solar Explains Pulmonary Embolism
-
Feb 1, 2026, 09:56Toni Lassila on Computational Models for Predicting Thrombus Formation
-
Feb 1, 2026, 09:45Nour Al-Mozain Contributs to 12th Edition of the Cell Therapy Standard and Global Transfusion Education
-
Feb 1, 2026, 09:26New Insights on Hypertriglyceridemia, Atherosclerosis, and Future Strategies to Reduce Cardiovascular Risk – EAS
-
Feb 1, 2026, 09:12Denis Oduor: Adapting Singapore’s Blood Transfusion Diagnostics Innovations to Strengthen Blood Systems in Nairobi